Company Overview of Weill Cornell Medical College, New York
Weill Cornell Medical College, New York is an educational institution.
525 East 68th Street
New York, NY 10065
Key Executives for Weill Cornell Medical College, New York
Weill Cornell Medical College, New York does not have any Key Executives recorded.
Weill Cornell Medical College, New York Key Developments
OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development
May 27 14
BioTime Inc. and its subsidiary OncoCyte Corporation announced that OncoCyte has entered into a License Agreement with Cornell University through which Weill Cornell Medical College will provide blood samples derived from healthy people and lung cancer patients for comparative analysis using the company's proprietary PanC-Dx(TM) diagnostic tests. OncoCyte scientists will determine levels of tumor-associated gene expression in these samples, including assessing levels of its proprietary PanC-Dx(TM) cancer markers. The results of these analyses, along with the results of the nearly complete clinical study currently being conducted by OncoCyte's collaborators at The Wistar Institute, will be combined to produce a data set from over 700 patients. This data will be used by OncoCyte to assess the performance of potential cancer markers for the purpose of developing a multi-marker test for the detection of lung cancer. As part of the License, OncoCyte retains all rights to develop and market its proprietary lung cancer diagnostic products. PanC-Dx(TM) is a novel class of noninvasive cancer diagnostics that are based on a proprietary set of cancer markers characterized, in part, by broad expression patterns in numerous cancer types. The performance of the marker panel in determining the presence or the progression of disease in various categories of patients will determine the specific nature of the test to be developed and the approval pathway that OncoCyte will pursue.
UCB Announces Strategic Research Alliance with Weill Cornell Medical College
Apr 7 14
UCB has announced a strategic research alliance with Weill Cornell Medical College to convert scientific discovery into transformative health improvements in areas of high patient need. UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine. The research programs are aligned with a key strategy of UCB NewMedicines to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.
Weill Cornell Medical College, New York Presents at Citigroup 2014 Global Healthcare Conference, Feb-26-2014 09:40 AM
Feb 11 14
Weill Cornell Medical College, New York Presents at Citigroup 2014 Global Healthcare Conference, Feb-26-2014 09:40 AM. Venue: Hilton New York, 1335 Avenue of the Americas (Between West 53rd - West 54th Streets), New York, NY 10019, United States. Speakers: Chris Mason, PhD, Assistant Professor.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries